{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:18:55Z","timestamp":1794651535037,"version":"4.9.1"},"reference-count":40,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Despite continued surveillance and intravesical therapy, a significant subset of patients with lamina propria\u2013invasive bladder cancer (T1) will progress to muscle-invasive disease or metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To analyze the value of pathologic subcategorization of T1 disease in predicting progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Six substaging methods were applied to a retrospective cohort of 73 patients, with pT1 urothelial carcinoma diagnosed on biopsy\/transurethral resection. Additionally, the immunohistochemistry for GATA3 and cytokeratin 5\/6 (CK5\/6) was performed to study the prognostic value of stratifying T1 cancers into luminal or basal phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>On follow-up (mean, 46 months), 21 patients (29%) experienced at least 1 recurrence without progression, and 16 (22%) had progression to muscle-invasive disease and\/or distant metastasis. No differences were noted between progressors and nonprogressors with regard to sex, age, treatment status, medical history, tumor grade, and presence of carcinoma in situ. Substaging using depth of invasion (cutoff \u22651.4 mm), largest invasive focus (\u22653.6 mm), aggregate linear length of invasion (\u22658.9 mm), and number of invasive foci (\u22653 foci) correlated significantly with progression and reduced progression-free survival, whereas invasion into muscularis mucosa or vascular plexus, or focal versus extensive invasion (focal when \u22642 foci, each &amp;lt;1 mm) failed. Patients with luminal tumors had higher incidence of progression than those with nonluminal tumors (27% versus 11%), although the difference was statistically insignificant (P = .14).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Substaging of T1 bladder cancers should be attempted in pathology reports. Quantifying the number of invasive foci (\u22653) and\/or measuring the largest contiguous focus of invasive carcinoma (\u22653.6 mm) are practical tools for prognostic substaging of T1 cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2021-0175-oa","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T16:42:27Z","timestamp":1638808947000},"page":"1131-1139","source":"Crossref","is-referenced-by-count":12,"title":["Subcategorization of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens for Predicting Progression"],"prefix":"10.5858","volume":"146","author":[{"given":"Anna","family":"Budina","sequence":"first","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar J.","family":"Farahani","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak)"},{"name":"Farahani is currently located at the Department of Pathology and Laboratory Medicine, Stony Brook University, Long Island, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Lal","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak)"},{"name":"The Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania (Lal, Nayak)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupma","family":"Nayak","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia (Budina, Farahani, Lal, Nayak)"},{"name":"The Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, Pennsylvania (Lal, Nayak)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"2022083122203421100_i1543-2165-146-9-1131-b01","doi-asserted-by":"crossref","unstructured":"Kirkali\n              Z,\n            \n            \n              Chan\n              T,\n            \n            \n              Manoharan\n              M,\n            \n            et al.\n          \n          Bladder cancer: epidemiology, staging and grading, and diagnosis.\n\t\t\t\t\tUrology.\n\t\t\t\t\t2005;66(6 suppl 1):4\u201334.","DOI":"10.1016\/j.urology.2005.07.062"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b02","doi-asserted-by":"crossref","unstructured":"Hall\n              MC,\n            \n            \n              Chang\n              SS,\n            \n            \n              Dalbagni\n              G,\n            \n            et al.\n          \n          Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2007;178(6):2314\u20132330.","DOI":"10.1016\/j.juro.2007.09.003"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b03","doi-asserted-by":"crossref","unstructured":"Shahin\n              O,\n            \n            \n              Thalmann\n              GN,\n            \n            \n              Rentsch\n              C,\n            \n            \n              Mazzucchelli\n              L,\n            \n            \n              Studer\n              UE.\n            \n          \n          A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2003;169(1):96\u2013100.","DOI":"10.1016\/S0022-5347(05)64044-X"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b04","doi-asserted-by":"crossref","unstructured":"Nepple\n              KG,\n            \n            \n              O'Donnell\n              MA.\n            \n          \n          The optimal management of T1 high-grade bladder cancer.\n\t\t\t\t\tCan Urol Assoc J.\n\t\t\t\t\t2009;3(6 suppl 4):S188\u2013S192.","DOI":"10.5489\/cuaj.1194"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b05","doi-asserted-by":"crossref","unstructured":"Herr\n              HW,\n            \n            \n              Reuter\n              VE.\n            \n          \n          Progression of T1 bladder tumors: better staging or better biology?\n          \n            Cancer\n          .\n\t\t\t\t\t1999;86(6):908\u2013912.","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<908::AID-CNCR2>3.0.CO;2-E"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b06","doi-asserted-by":"crossref","unstructured":"Andius\n              P,\n            \n            \n              Johansson\n              SL,\n            \n            \n              Holm\u00e4ng\n              S.\n            \n          \n          Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion.\n\t\t\t\t\tUrology.\n\t\t\t\t\t2007;70(4):758\u2013762.","DOI":"10.1016\/j.urology.2007.06.638"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b07","doi-asserted-by":"crossref","unstructured":"Fernandez-Gomez\n              J,\n            \n            \n              Madero\n              R,\n            \n            \n              Solsona\n              E,\n            \n            et al.\n          \n          Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2009;182(5):2195\u20132203.","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b08","doi-asserted-by":"crossref","unstructured":"Sylvester\n              RJ,\n            \n            \n              van der Meijden\n              APM,\n            \n            \n              Oosterlinck\n              W,\n            \n            et al.\n          \n          Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2006;49(3):466\u2013477.","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b09","doi-asserted-by":"crossref","unstructured":"Segal\n              R,\n            \n            \n              Yafi\n              FA,\n            \n            \n              Brimo\n              F,\n            \n            \n              Tanguay\n              S,\n            \n            \n              Aprikian\n              A,\n            \n            \n              Kassouf\n              W.\n            \n          \n          Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?\n          \n            BJU Int\n          .\n\t\t\t\t\t2012;109(7):1026\u20131030.","DOI":"10.1111\/j.1464-410X.2011.10462.x"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b10","doi-asserted-by":"crossref","unstructured":"Shariat\n              SF,\n            \n            \n              Zippe\n              C,\n            \n            \n              L\u00fcdecke\n              G,\n            \n            et al.\n          \n          Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2005;173(5):1518\u20131525.","DOI":"10.1097\/01.ju.0000154696.48217.75"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b11","doi-asserted-by":"crossref","unstructured":"Younes\n              M,\n            \n            \n              Sussman\n              J,\n            \n            \n              True\n              LD.\n            \n          \n          The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder.\n\t\t\t\t\tCancer.\n\t\t\t\t\t1990;66(3):543\u2013548.","DOI":"10.1002\/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b12","doi-asserted-by":"crossref","unstructured":"Smits\n              G,\n            \n            \n              Schaafsma\n              E,\n            \n            \n              Kiemeney\n              L,\n            \n            \n              Caris\n              C,\n            \n            \n              Debruyne\n              F,\n            \n            \n              Witjes\n              JA.\n            \n          \n          Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.\n\t\t\t\t\tUrology.\n\t\t\t\t\t1998;52(6):1009\u20131014.","DOI":"10.1016\/S0090-4295(98)00374-4"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b13","doi-asserted-by":"crossref","unstructured":"Cheng\n              L,\n            \n            \n              Weaver\n              AL,\n            \n            \n              Neumann\n              RM,\n            \n            \n              Scherer\n              BG,\n            \n            \n              Bostwick\n              DG.\n            \n          \n          Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal.\n\t\t\t\t\tCancer.\n\t\t\t\t\t1999;86(6):1035\u20131043.","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b14","doi-asserted-by":"crossref","unstructured":"van der Aa\n              MN,\n            \n            \n              van Leenders\n              GJ,\n            \n            \n              Steyerberg\n              EW,\n            \n            et al.\n          \n          A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation.\n\t\t\t\t\tHum Pathol.\n\t\t\t\t\t2005;36(9):981\u2013986.","DOI":"10.1016\/j.humpath.2005.06.017"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b15","doi-asserted-by":"crossref","unstructured":"Hu\n              Z,\n            \n            \n              Mudaliar\n              K,\n            \n            \n              Quek\n              ML,\n            \n            \n              Paner\n              GP,\n            \n            \n              Barkan\n              GA.\n            \n          \n          Measuring the dimension of invasive component in pT1 urothelial carcinoma in transurethral resection specimens can predict time to recurrence.\n\t\t\t\t\tAnn Diagn Pathol.\n\t\t\t\t\t2014;18(2):49\u201352.","DOI":"10.1016\/j.anndiagpath.2013.11.002"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b16","doi-asserted-by":"crossref","unstructured":"Leivo\n              MZ,\n            \n            \n              Sahoo\n              D,\n            \n            \n              Hamilton\n              Z,\n            \n            et al.\n          \n          Analysis of T1 bladder cancer on biopsy and transurethral resection specimens: comparison and ranking of T1 quantification approaches to predict progression to muscularis propria Invasion.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2018;42(1):e1\u2013e10.","DOI":"10.1097\/PAS.0000000000000964"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b17","doi-asserted-by":"crossref","unstructured":"Hasui\n              Y,\n            \n            \n              Osada\n              Y,\n            \n            \n              Kitada\n              S,\n            \n            \n              Nishi\n              S.\n            \n          \n          Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer.\n\t\t\t\t\tUrology.\n\t\t\t\t\t1994;43(6):782\u2013786.","DOI":"10.1016\/0090-4295(94)90134-1"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b18","doi-asserted-by":"crossref","unstructured":"Angulo\n              JC,\n            \n            \n              Lopez\n              JI,\n            \n            \n              Grignon\n              DJ,\n            \n            \n              Sanchez-Chapado\n              M.\n            \n          \n          Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer.\n\t\t\t\t\tUrology.\n\t\t\t\t\t1995;45(1):47\u201353.","DOI":"10.1016\/S0090-4295(95)96490-8"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b19","doi-asserted-by":"crossref","unstructured":"Holm\u00e4ng\n              S,\n            \n            \n              Hedelin\n              H,\n            \n            \n              Anderstr\u00f6m\n              C,\n            \n            \n              Holmberg\n              E,\n            \n            \n              Johansson\n              SL.\n            \n          \n          The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t1997;157(3):800\u2013804.","DOI":"10.1016\/S0022-5347(01)65044-4"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b20","doi-asserted-by":"crossref","unstructured":"Roupr\u00eat\n              M,\n            \n            \n              Seisen\n              T,\n            \n            \n              Comp\u00e9rat\n              E,\n            \n            et al;\n            Comit\u00e9 de Canc\u00e9rologie de l'Association Fran\u00e7aise d'Urologie.\n          \n          Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2013;189(6):2069\u20132076.","DOI":"10.1016\/j.juro.2012.11.120"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b21","doi-asserted-by":"crossref","unstructured":"Orsola\n              A,\n            \n            \n              Trias\n              I,\n            \n            \n              Ravent\u00f3s\n              CX,\n            \n            et al.\n          \n          Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a\/b\/c) in BCG-treated and BCG-non-treated patients.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2005;48(2):231\u2013238.","DOI":"10.1016\/j.eururo.2005.04.013"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b22","doi-asserted-by":"crossref","unstructured":"Lee\n              JY,\n            \n            \n              Joo\n              HJ,\n            \n            \n              Cho\n              DS,\n            \n            \n              Kim\n              SI,\n            \n            \n              Ahn\n              HS,\n            \n            \n              Kim\n              SJ.\n            \n          \n          Prognostic significance of substaging according to the depth of lamina propria invasion in primary T1 transitional cell carcinoma of the bladder.\n\t\t\t\t\tKorean J Urol.\n\t\t\t\t\t2012;53(5):317\u2013323.","DOI":"10.4111\/kju.2012.53.5.317"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b23","doi-asserted-by":"crossref","unstructured":"Orsola\n              A,\n            \n            \n              Werner\n              L,\n            \n            \n              de Torres\n              I,\n            \n            et al.\n          \n          Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients.\n\t\t\t\t\tBr J Cancer.\n\t\t\t\t\t2015;112(3):468\u2013474.","DOI":"10.1038\/bjc.2014.633"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b24","doi-asserted-by":"crossref","unstructured":"Chang\n              W-C,\n            \n            \n              Chang\n              Y-H,\n            \n            \n              Pan\n              C-C.\n            \n          \n          Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2012;36(3):454\u2013461.","DOI":"10.1097\/PAS.0b013e31823dafd3"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b25","doi-asserted-by":"crossref","unstructured":"Humphrey\n              PA,\n            \n            \n              Moch\n              H,\n            \n            \n              Cubilla\n              AL,\n            \n            \n              Ulbright\n              TM,\n            \n            \n              Reuter\n              VE.\n            \n          \n          The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2016;70(1):106\u2013119.","DOI":"10.1016\/j.eururo.2016.02.028"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b26","doi-asserted-by":"crossref","unstructured":"Sj\u00f6dahl\n              G,\n            \n            \n              Lauss\n              M,\n            \n            \n              L\u00f6vgren\n              K,\n            \n            et al.\n          \n          A molecular taxonomy for urothelial carcinoma.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2012;18(12):3377\u20133386.","DOI":"10.1158\/1078-0432.CCR-12-0077-T"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b27","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network.\n          Comprehensive molecular characterization of urothelial bladder carcinoma.\n\t\t\t\t\tNature.\n\t\t\t\t\t2014;507(7492):315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b28","doi-asserted-by":"crossref","unstructured":"Choi\n              W,\n            \n            \n              Czerniak\n              B,\n            \n            \n              Ochoa\n              A,\n            \n            et al.\n          \n          Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.\n\t\t\t\t\tNat Rev Urol.\n\t\t\t\t\t2014;11(7):400\u2013410.","DOI":"10.1038\/nrurol.2014.129"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b29","doi-asserted-by":"crossref","unstructured":"Seiler\n              R,\n            \n            \n              Ashab\n              HAD,\n            \n            \n              Erho\n              N,\n            \n            et al.\n          \n          Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2017;72(4):544\u2013554.","DOI":"10.1016\/j.eururo.2017.03.030"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b30","doi-asserted-by":"crossref","unstructured":"Choi\n              W,\n            \n            \n              Porten\n              S,\n            \n            \n              Kim\n              S,\n            \n            et al.\n          \n          Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.\n\t\t\t\t\tCancer Cell.\n\t\t\t\t\t2014;25(2):152\u2013165.","DOI":"10.1016\/j.ccr.2014.01.009"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b31","doi-asserted-by":"crossref","unstructured":"Dadhania\n              V,\n            \n            \n              Zhang\n              M,\n            \n            \n              Zhang\n              L,\n            \n            et al.\n          \n          Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use.\n\t\t\t\t\tEBioMedicine.\n\t\t\t\t\t2016;12:\n\t\t\t\t\t105\u2013117.\n\t\t\t\t\tdoi:10.1016\/j.ebiom. 2016.08.036","DOI":"10.1016\/j.ebiom.2016.08.036"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b32","doi-asserted-by":"crossref","unstructured":"Hedegaard\n              J,\n            \n            \n              Lamy\n              P,\n            \n            \n              Nordentoft\n              I,\n            \n            et al.\n          \n          Comprehensive transcriptional analysis of early-stage urothelial carcinoma.\n\t\t\t\t\tCancer Cell.\n\t\t\t\t\t2016;30(1):27\u201342.","DOI":"10.1016\/j.ccell.2016.05.004"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b33","doi-asserted-by":"crossref","unstructured":"Breyer\n              J,\n            \n            \n              Wirtz\n              RM,\n            \n            \n              Otto\n              W,\n            \n            \n              Erben\n              P,\n            \n            et al.\n          \n          In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.\n\t\t\t\t\tVirchows Arch.\n\t\t\t\t\t2017;470(3):267\u2013274.","DOI":"10.1007\/s00428-017-2064-8"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b34","doi-asserted-by":"crossref","unstructured":"Patschan\n              O,\n            \n            \n              Sj\u00f6dahl\n              G,\n            \n            \n              Chebil\n              G,\n            \n            et al.\n          \n          A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2015;68(5):824\u2013832.","DOI":"10.1016\/j.eururo.2015.02.021"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b35","doi-asserted-by":"crossref","unstructured":"Rebola\n              J,\n            \n            \n              Aguiar\n              P,\n            \n            \n              Blanca\n              A,\n            \n            et al.\n          \n          Predicting outcomes in non-muscle invasive (Ta\/T1) bladder cancer: the role of molecular grade based on luminal\/basal phenotype.\n\t\t\t\t\tVirchows Arch.\n\t\t\t\t\t2019;475(4):445\u2013455.","DOI":"10.1007\/s00428-019-02593-x"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b36","doi-asserted-by":"crossref","unstructured":"Rodriguez Pena\n              MDC,\n            \n            \n              Chaux\n              A,\n            \n            \n              Eich\n              ML,\n            \n            et al.\n          \n          Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.\n\t\t\t\t\tVirchows Arch.\n\t\t\t\t\t2019;475(3):349\u2013356.","DOI":"10.1007\/s00428-019-02618-5"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b37","unstructured":"Platz\n              CE,\n            \n            \n              Cohen\n              MB,\n            \n            \n              Jones\n              MP,\n            \n            \n              Olson\n              DB,\n            \n            \n              Lynch\n              CF.\n            \n          \n          Is microstaging of early invasive cancer of the urinary bladder possible or useful?\n          \n            Mod Pathol\n          .\n\t\t\t\t\t1996;9(11):1035\u20131039."},{"key":"2022083122203421100_i1543-2165-146-9-1131-b38","doi-asserted-by":"crossref","unstructured":"van Rhijn\n              BW,\n            \n            \n              van der Kwast\n              TH,\n            \n            \n              Alkhateeb\n              SS,\n            \n            et al.\n          \n          A new and highly prognostic system to discern T1 bladder cancer substage.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2012;61(2):378\u2013384.","DOI":"10.1016\/j.eururo.2011.10.026"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b39","doi-asserted-by":"crossref","unstructured":"Patriarca\n              C,\n            \n            \n              Hurle\n              R,\n            \n            \n              Moschini\n              M,\n            \n            et al.\n          \n          Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.\n\t\t\t\t\tDiagn Pathol.\n\t\t\t\t\t2016;11:\n\t\t\t\t\t6.","DOI":"10.1186\/s13000-016-0466-6"},{"key":"2022083122203421100_i1543-2165-146-9-1131-b40","doi-asserted-by":"crossref","unstructured":"Brimo\n              F,\n            \n            \n              Wu\n              C,\n            \n            \n              Zeizafoun\n              N,\n            \n            et al.\n          \n          Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion.\n\t\t\t\t\tHum Pathol.\n\t\t\t\t\t2013;44(1):95\u2013102.","DOI":"10.1016\/j.humpath.2012.04.020"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/9\/1131\/3111205\/i1543-2165-146-9-1131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/9\/1131\/3111205\/i1543-2165-146-9-1131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:26Z","timestamp":1764790886000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/146\/9\/article-p1131.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,12,6]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2021-0175-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,6]]}}}